Novasenta aims to meet that need by utilizing our team’s exceptional capacity to comprehend the intricate relationships between various tumor types and the immune system. Unfortunately, only a small portion of patients benefit from these cutting-edge treatments, leaving a significant unmet need for efficient therapy. “Checkpoint inhibitors and CAR T-cell treatments, among other immunotherapies, have changed cancer treatment and enhanced patient outcomes. She mentioned that over the previous 12 months, the company had increased the size of its senior management team by bringing in executives with a track record of success in the drug development industry. As we work to bring life-saving treatments to market, our distinctive target discovery and validation technology, accessibility to patient tumor samples, and the experience of our founders are crucial advantages.” ![]() Our cooperation with UPMC and UPMC Enterprises is only one of many benefits driving the expansion of Novasenta, especially in these difficult times. ![]() “With our sizeable Series A funding, Novasenta anticipates putting at least one of our three shortlisted programs into practice by 2024, which has the potential to revolutionize how solid tumor patients are treated. Chief executive of Novasenta and seasoned biotechnology executive Mani Mohindru, Ph.D. ![]() The money will enable Novasenta to develop its computational tools for target identification and enhance its pipeline of antibody-based therapies, all while retaining outstanding staff. Pittsburgh, JUPMC Enterprises, the innovation, venture capital, and commercialization arm of top healthcare system UPMC, sponsored the USD 40 million Series A funding for Novasenta Inc., a new biotechnology firm focused on the discovery and validation of novel targets to create cancer medicines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |